Carolina Gastelum Guerrero

Carolina Gastelum Guerrero

Auto-generated profile, based on publicly available information

Carolina Gastelum Guerrero

Posgrado en Ciencias en Biomedicina Molecular, Facultad de Medicina Universidad Autónoma de Sinaloa Culiacán Sinaloa Mexico

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2024 in Journal of Intellectual Disability Research
Verified
Journal Article
Closed access
CGCarolina Gastelum Guerrero
Carolina Gastelum Guerrero
YFYuridia Lizet Cháidez Fernández
Yuridia Lizet Cháidez Fernández
DODalia Magaña Ordorica
Dalia Magaña Ordorica
HBHeidi Berger
Heidi Berger
MLMarilyn Vazquez Landrove
Marilyn Vazquez Landrove
JGJavier Magaña Gómez
Javier Magaña Gómez

11 June 2026 in Journal of Intellectual Disability Research
Verified
Journal Article
Open access
PDF file
CGCarolina Gastélum Guerrero
Carolina Gastélum Guerrero
ALALMA MARLENE GUADRON LLANOS
ALMA MARLENE GUADRON LLANOS
LCLoranda Calderón-Zamora
Loranda Calderón-Zamora
Alberto Kousuke De la Herrán-AritaAlberto Kousuke De la Herrán-Arita
Alberto Kousuke De la Herrán-Arita
YCYair Cruz-Narváez
Yair Cruz-Narváez
JGJavier Magaña Gómez
Javier Magaña Gómez
Background: Individuals with Down syndrome (DS) face a high burden of health complications, yet the molecular underpinnings remain incompletely defined. Objective: The objective of this study is to systematically identify metabolomic changes in individuals with DS and how they relate to DS‐associated conditions. Methods: A scoping review of the literature was performed across four online databases to identify studies profiling metabolites in people with DS using untargeted or targeted metabolomics procedures. The findings were narratively synthesised to provide a comprehensive overview of patterns of convergence and variability across studies. Results: Thirty‐four studies examining metabolites in individuals with DS were identified. The combined findings revealed widespread disruptions in energy (e.g., tricarboxylic acid cycle intermediates and acylcarnitines), one‐carbon (e.g., methionine and the SAM/SAH axis), amino acid (e.g., tryptophan‐kynurenine and glutamate/GABA) and lipid (e.g., phospholipids and sphingolipids) metabolism, along with changes in immune and neurotransmitter pathways. These metabolic alterations are associated with phenotypic variability and comorbidities in DS. However, the evidence reflects partially convergent and context‐dependent patterns, with substantial variability across studies. Conclusion: Metabolic disturbances are common in DS, suggesting candidate metabolic signatures that still require independent replication and validation. Current evidence is predominantly cross‐sectional and associative, limiting causal inference. Integrating metabolomics with multi‐omics approaches may enhance the understanding of DS‐related health issues and support future translation into clinical applications.